Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?

Por Pérez-García, José, Cortés, Javier
Publicado em 2012

Pushing the envelope in the mTOR pathway. The second generation of inhibitors

Por Vilar, Eduardo, Perez-Garcia, Jose, Tabernero, Josep
Publicado em 2011

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

Por Muñoz-Couselo, Eva, Pérez-García, José, Cortés, Javier
Publicado em 2011

Bone metastases: Causes, consequences and therapeutic opportunities

Por Perez-Garcia, Jose, Muñoz-Couselo, Eva, Cortes, Javier
Publicado em 2013

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors

Por Muñoz-Couselo, Eva, García, Jesús Soberino, Pérez-García, José Manuel, Cebrián, Vanesa Ortega, Castán, Javier Cortés
Publicado no Ann Transl Med (2015)

Design of splints based on the NiTi alloy for the correction of joint deformities in the fingers

Por Puértolas Sergio, Pérez-García José M, Gracia Luis, Cegoñino José, Ibarz Elena, Puértolas José A, Herrera Antonio
Publicado em 2010-09-01

Design of splints based on the NiTi alloy for the correction of joint deformities in the fingers

Por Puértolas, Sergio, Pérez-García, José M, Gracia, Luis, Cegoñino, José, Ibarz, Elena, Puértolas, José A, Herrera, Antonio
Publicado em 2010

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer pati...

Por De Mattos-Arruda, Leticia, Bottai, Giulia, Nuciforo, Paolo G., Di Tommaso, Luca, Giovannetti, Elisa, Peg, Vicente, Losurdo, Agnese, Pérez-Garcia, José, Masci, Giovanna, Corsi, Fabio, Cortés, Javier, Seoane, Joan, Calin, George A., Santarpia, Libero
Publicado no Oncotarget (2015)

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy

Por Nuciforo, Paolo, Thyparambil, Sheeno, Aura, Claudia, Garrido-Castro, Ana, Vilaro, Marta, Peg, Vicente, Jimenez, José, Vicario, Rocio, Cecchi, Fabiola, Hoos, William, Burrows, Jon, Hembrough, Todd, Ferreres, Juan Carles, Perez-Garcia, José, Arribas, Joaquin, Cortes, Javier, Scaltriti, Maurizio
Publicado no Mol Oncol (2015)

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Por Serra, Violeta, Eichhorn, Pieter J.A., García-García, Celina, Ibrahim, Yasir H., Prudkin, Ludmila, Sánchez, Gertrudis, Rodríguez, Olga, Antón, Pilar, Parra, Josep-Lluís, Marlow, Sara, Scaltriti, Maurizio, Pérez-Garcia, José, Prat, Aleix, Arribas, Joaquín, Hahn, William C., Kim, So Young, Baselga, José
Publicado em 2013

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Por Serra, Violeta, Eichhorn, Pieter J.A., García-García, Celina, Ibrahim, Yasir H., Prudkin, Ludmila, Sánchez, Gertrudis, Rodríguez, Olga, Antón, Pilar, Parra, Josep-Lluís, Marlow, Sara, Scaltriti, Maurizio, Pérez-Garcia, José, Prat, Aleix, Arribas, Joaquín, Hahn, William C., Kim, So Young, Baselga, José
Publicado em 2014

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Por Bosch, Ana, Li, Zhiqiang, Bergamaschi, Anna, Ellis, Haley, Toska, Eneda, Prat, Aleix, Tao, Jessica J., Spratt, Daniel E., Viola-Villegas, Nerissa T., Castel, Pau, Minuesa, Gerard, Morse, Natasha, Rodón, Jordi, Ibrahim, Yasir, Cortes, Javier, Perez-Garcia, Jose, Galvan, Patricia, Grueso, Judit, Guzman, Marta, Katzenellenbogen, John A., Kharas, Michael, Lewis, Jason S., Dickler, Maura, Serra, Violeta, Rosen, Neal, Chandarlapaty, Sarat, Scaltriti, Maurizio, Baselga, José
Publicado no Sci Transl Med (2015)